NCT07069270 2025-07-16
A Study on the First-line Treatment of Small Cell Lung Cancer With Adebrelimab and Vunakizumab and Chemotherapy
Fujian Cancer Hospital
Phase 2 Not yet recruiting
Clinical Trials
17 trialsNCT06786312 2025-01-22
A Single-arm, Multicenter, Prospective Phase II Clinical Study of Apatinib in Combination With Adebrelimab and EC Regimen in the First-line Treatment of Extensive Small Cell Lung Cancer
Fujian Cancer Hospital
Phase 2 Not yet recruiting
NCT06614621 2024-09-26
A Study of Adebelimab Combined With Chemotherapy as a First-line Treatment Sequential Treatment for Extensive-stage Small Cell Lung Cancer
Fujian Cancer Hospital
Phase 2 Not yet recruiting
NCT06236997 2024-02-01
Adebrelimab and Concurrent Radiochemotherapy as First-line Treatment for Extensive-stage Small-cell Lung Cancer
Henan Cancer Hospital
Phase 2 Not yet recruiting
NCT05595889 2022-11-29
Surufatinib Combined With Irinotecan as a Second-line Treatment for Small Cell Lung Cancer
Fujian Cancer Hospital
Phase 2 Unknown
NCT04660097 2022-04-12
Alotinib Plus Durvalumab-Platinum-Etoposide in First-line Treatment Extensive Small-cell Lung Cancer
Henan Cancer Hospital
Phase 2 Unknown
NCT01441349 2022-04-06
Irinotecan/Cisplatin With or Without Simvastatin in Chemo-naive Patients With Extensive Disease-small Cell Lung Cancer
National Cancer Center, Korea
Phase 2 Unknown
NCT05299255 2022-03-28
Utidelone in Third-line and Above Treatment of Small Cell Lung Cancer
Henan Cancer Hospital
Phase 2 Unknown
NCT04901754 2021-12-08
CAMERA
Henan Cancer Hospital
Phase 2 Unknown
NCT03389087 2020-07-10
Study of Apatinib Plus Etoposide Capsule as the Therapy of Advanced Small Cell Lung Cancer
Henan Cancer Hospital
Phase 2 Unknown
NCT03983759 2020-06-11
Study of Sintlimab Maintenance Therapy in Patients With Extensive Small Cell Lung Cancer
Henan Cancer Hospital
Phase 2 Unknown
NCT01441297 2017-08-25
BIBF 1120 as Second Line Treatment for Small Cell Lung Cancer
National Cancer Center, Korea
Phase 2 Completed
NCT02980809 2016-12-02
Topotecan Plus Apatinib Versus Topotecan Alone as Second-line Therapy in Small-cell Lung Cancer
First Hospitals affiliated to the China PLA General Hospital
Phase 2 Unknown
NCT01159327 2015-11-11
Study of Sorafenib Maintenance in Patients With ED-SCLC After Response to Induction Chemotherapy
National Cancer Center, Korea
Phase 2 Terminated
NCT00452634 2013-06-19
Irinotecan/Cisplatin Plus Simvastatin in Extensive Disease-Small Cell Lung Cancer (ED-SCLC)
National Cancer Center, Korea
Phase 2 Completed
NCT00620347 2013-06-19
Sunitinib as a Second-line Treatment for Patients With Recurrent Small Cell Lung Cancer
National Cancer Center, Korea
Phase 2 Completed
NCT00453167 2010-07-12
Weekly Paclitaxel Plus Gemcitabine as Second-line in Small Cell Lung Cancer
National Cancer Center, Korea
Phase 2 Completed